NCT06720987View on ClinicalTrials.gov

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2030

Conditions
KRAS G12C MutationKRAS G12S MutationSolid Tumor MalignanciesCRC (Colorectal Cancer)
Interventions
DRUG

KQB365

Intravenous KQB365

DRUG

Cetuximab

Intravenous cetuximab

Trial Locations (9)

22031

RECRUITING

NEXT Virginia, LLC, Fairfax

32224

RECRUITING

Mayo Clinic, Jacksonville, Jacksonville

44195

RECRUITING

Cleveland Clinic, Taussig Cancer Institute, Cleveland

49546

RECRUITING

START Midwest, Grand Rapids

55905

RECRUITING

Mayo Clinic, Rochester, Rochester

78229

RECRUITING

NEXT Oncology, San Antonio

80218

RECRUITING

Sarah Cannon Cancer Institute at HealthONE, Denver

85054

RECRUITING

Mayo Clinic, Phoenix, Phoenix

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Kumquat Biosciences Inc.

INDUSTRY

NCT06720987 - A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter